

WuXi, Tsinghua announce strategic partnership

May 30, 2018 | News

Through this partnership ICIT will have access to WuXi Biologics' comprehensive, integrated services.



WuXi Biologics, a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, and Tsinghua University Innovation Center for Immune Therapy (ICIT), have formed a strategic partnership in discovery, development and manufacturing of biologics.

ICIT focuses on discovery and development of therapies for immune and cancer diseases. Through this partnership ICIT will have access to WuXi Biologics' comprehensive, integrated services including innovative biologics discovery, cell line development, cell culture process development, purification process development and formulation development and manufacturing for ICIT's monoclonal antibodies, bispecific antibodies, recombinant proteins, and protein conjugates (i.e., ADCs).

Tsinghua University Innovation Center for Immune Therapy (ICIT), a joint entity of the Institutes for Immunology and Institute of Technology Transfer at Tsinghua University, was established in August, 2016. ICIT aims to accelerate transformation of basic scientific discoveries into innovative medicines.